Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Total Current Liabilities (2016 - 2026)

Lexaria Bioscience's Total Current Liabilities history spans 11 years, with the latest figure at $214671.0 for Q1 2026.

  • Quarterly results put Total Current Liabilities at $214671.0 for Q1 2026, down 88.22% from a year ago — trailing twelve months through Feb 2026 was $214671.0 (down 88.22% YoY), and the annual figure for FY2025 was $1.5 million, up 35.84%.
  • Total Current Liabilities for Q1 2026 was $214671.0 at Lexaria Bioscience, down from $1.5 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $1.8 million in Q1 2025 to a low of $81717.0 in Q1 2024.
  • The 5-year median for Total Current Liabilities is $267735.0 (2023), against an average of $625259.7.
  • The sharpest move saw Total Current Liabilities soared 2130.16% in 2025, then crashed 88.22% in 2026.
  • Year by year, Total Current Liabilities stood at $281520.0 in 2022, then tumbled by 55.77% to $124523.0 in 2023, then skyrocketed by 139.15% to $297798.0 in 2024, then soared by 389.1% to $1.5 million in 2025, then crashed by 85.26% to $214671.0 in 2026.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $214671.0, $1.5 million, and $1.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.